Indications and Usage IOPIDINE 1% Ophthalmic Solution is indicated to control or prevent post-surgical elevations in IOP that occur in patients after argon laser trabeculoplasty, argon laser iridotomy ...
Glaukos Corporation announced that the US Centers for Medicare and Medicaid Services (CMS) has assigned a permanent ...
Zacks Investment Research on MSN
Glaukos wins permanent J-code for Epioxa keratoconus therapy
Glaukos GKOS announced that its innovative keratoconus treatment, Epioxa (Epioxa HD / Epioxa), was assigned a permanent HCPCS ...
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, ...
East Brunswick’s Savient Pharmaceuticals Inc. is starting the new year with a major boost. Savient’s chronic gout drug, Krystexxa, now has its own permanent billing code from the Centers for Medicare ...
Pacira BioSciences (NASDAQ:PCRX) on Thursday announced that the U.S. Centers for Medicare and Medicaid Services (CMS) issued a product-specific J-code for its non-opioid pain therapy Exparel for ...
The aflibercept 8 mg injection improves patient care by allowing longer intervals between treatments, explains Jose A. Martinez, MD, Austin Retina Associates. A new Healthcare Common Procedure Coding ...
-- BARHEMSYS is the first and only antiemetic approved by the FDA for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis1 and is also approved for the treatment of PONV ...
Please provide your email address to receive an email when new articles are posted on . Ycanth has received a permanent J-code for the treatment of molluscum contagiosum. The code will be fully ...
How a strong collaboration between clinical and billing teams can simplify J-code decoding, paving the way for improved patient access to innovative treatments. It’s an all-too-common story. A patient ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code ...
Glaukos has received a permanent U.S. reimbursement code for its incision-free keratoconus therapy Epioxa, effective July 1, 2026. The J-code is expected to streamline billing, expand insurance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results